Overexpression or the amplification of HER2 oncogene, leading to overexpression of this transmembrane tyrosine kinase receptor, is present in approximately 15–25% of all breast cancers, and it is more likely to be diagnosed in younger patients and at a more advanced stage [7,9,10,11]. Here, ERBB2 is linked to breast cancer.